Survival of breast cancer patients treated with inhibitors of the aromatasa vs tamoxifen;Supervivencia de pacientes con cáncer de mama tratadas con inhibidores de la aromatización vs tamoxifeno

Ginecologia y Obstetricia de Mexico

Volumn 72, Issue 10, 2004, Pages 493-499

  Rico, Germán Castelazo ^a   Xolalpa, Donaji Molotla ^a   Rodríguez, María Antonia Basavilvazo ^a   Victoria, Leobardo Ángeles ^a   Zárate, Arturo ^a   Valencia, Marcelino Hernández ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Anastrozole; Breast cancer; Survival; Tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; INTRADUCTAL CARCINOMA; MASTECTOMY; MEXICO; PREOPERATIVE TREATMENT; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NITRILES; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES;

EID: 20644435789     PISSN: 03009041     EISSN: 03009041     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Registro Histopatológico de Neoplasias Malignas en México. Secretaría de Salubridad, 1997.
2. Dirección General de Estadística: Base de defunciones 1979-1994. México: Instituto Nacional de Estadística, Geografía e Informática, 1996.
3. Zárate A, Hernández-Valencia M. Terapia de reemplazo hormonal en mujeres menopáusicas tratadas por cáncer mamario. Rev Med IMSS 2002;40:369-71.
4. Muller V. Partial antagonist between steroidal and nonesteroidal antiestrogens in human breast cancer cell lines. Cancer Res 1998;15:263-67.
5. Sainsbury R. Ovarian ablation as a treatment for breast cancer. Surg Oncol 2003;12:241-50.
6. Grana G. New developments in endocrine therapy: role of adjuvant therapy in early breast cancer. Cancer Nurs 2003;26:4-9.
7. Barnes DM, Millis RR, Gillett CE, Ryder K, et al. The interaction of oestrogen receptor status and pathological with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients. Endocr Relat Cancer 2004;11:85-86.
8. Bonnete J. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 1999;92:2247-58.
9. Lonning PE. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Ann 2002;19:277-98.
10. Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat 2004;85:89-97.
11. Jordan VC. Tamoxifen: a personal retrospective. Lancet Oncol 2000;1:43-49.
12. Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 2004;31:54-63.
13. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 2004;31:28-38.
14. Buzdar AU. Anastrozole (Arimidex) - an aromatase inhibidor for the adyuvant setting? Br J Cancer 2001;85:6-10.
15. Koberle D. Anastrozole: pharmacological and clinical profile in postmenopausal woman with breast cancer. Expert Rev Anticancer Ther 2001;1:169-76.
16. Rodríguez-Cuevas S, Macías-Martínez CG, Labastida Almendaro S. Cáncer de mama en México. ¿Una enfermedad de mujeres jóvenes? Ginecol Obstet Mex 2000;68:185-90.
17. Salazar EL, García MO, Ávila A. Factores de riesgo y correlación con algunos marcadores tumorales en la incidencia de cáncer de mama en pacientes pre y postmenopáusicas. Ginecol Obstet Mex 1998;66:263-6.
18. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reynoso L, Steer O. Clinical practoce guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 2004;16(170):983-4.
19. Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer CMF-7 cells by a mechanism of NF-kB-dependent XIAP. J Biol Chem 2004;20:150-4.
20. Cheng G, Imamov O, Omoto Y, Warner M, Gustafsson JA. GAT is the value of measuring MTA-1s in breast cancer? Mol Intervent 2002;6:360-2.